INCLUSION OF IVERMECTIN IN THE FIRST LINE OF THERAPEUTIC ACTION FOR COVID-19 A very significant decrease in the Fatality Rate is reported with its use (Peru 2020-05 Aguirre)
The existing evidence as of April 30, 2020 regarding the use of Ivermectin in COVID-19 is reviewed. A report is also made of part of the cases treated at the local level to date. A study made available on the web on April 3, 2020 in the journal Antiviral Research, found that in vitro with a single dose of Ivermectin, SARS-CoV-2 was reduced by 99.8% after 48 hours. Subsequently, on April 19, 2020, a study was made available on the SSRN website that obtained participants from 169 hospitals around the world, this study includes 704 patients treated with Ivermectin, and their corresponding 704 controls. The study results indicate that the case fatality rate in hospitalized patients who used Ivermectin was 6.1 times lower compared to patients who did not use Ivermectin (1.4 vs 8.5%). For his part, in the Dominican Republic, the Pulmonologist Johnny Tavares reports that he is treating 247 patients with Ivermectin with a favorable response in all cases and has not manifested any fatal case. Similarly, at the local level, although to date there are not many documented cases, it is evident that the use of Ivermectin results in a very significant decrease in the Fatality Rate and it is also observed that in 100% of the cases treated with Ivermectin there is an improvement in the disease and resolution of the fever within 48 hours of starting treatment. A New Therapeutic Scheme is presented according to the Degree of Severity and Response to Treatment, prepared based on the experience of patients treated locally. In the final part, an evaluation of the Risk-Benefit of the use of Ivermectin is made, the Conclusion is given that, since there is practically no risk in its use, it is recommended to formalize its inclusion in the first line of therapeutic action for COVID-19. Finally, Recommendations are given mainly related to the supply in Health Establishments throughout the country.
[-] TrumpLyftAlles | 1 points | Aug 27 2020 04:00:16
TLATODO: Annotate
The existing evidence as of April 30, 2020 regarding the use of Ivermectin in COVID-19 is reviewed. A report is also made of part of the cases treated at the local level to date. A study made available on the web on April 3, 2020 in the journal Antiviral Research, found that in vitro with a single dose of Ivermectin, SARS-CoV-2 was reduced by 99.8% after 48 hours. Subsequently, on April 19, 2020, a study was made available on the SSRN website that obtained participants from 169 hospitals around the world, this study includes 704 patients treated with Ivermectin, and their corresponding 704 controls. The study results indicate that the case fatality rate in hospitalized patients who used Ivermectin was 6.1 times lower compared to patients who did not use Ivermectin (1.4 vs 8.5%). For his part, in the Dominican Republic, the Pulmonologist Johnny Tavares reports that he is treating 247 patients with Ivermectin with a favorable response in all cases and has not manifested any fatal case. Similarly, at the local level, although to date there are not many documented cases, it is evident that the use of Ivermectin results in a very significant decrease in the Fatality Rate and it is also observed that in 100% of the cases treated with Ivermectin there is an improvement in the disease and resolution of the fever within 48 hours of starting treatment. A New Therapeutic Scheme is presented according to the Degree of Severity and Response to Treatment, prepared based on the experience of patients treated locally. In the final part, an evaluation of the Risk-Benefit of the use of Ivermectin is made, the Conclusion is given that, since there is practically no risk in its use, it is recommended to formalize its inclusion in the first line of therapeutic action for COVID-19. Finally, Recommendations are given mainly related to the supply in Health Establishments throughout the country.
Table 3
Source
permalink